SCHEDULE: PAVmed Amends Lucid Diagnostics Stake, Adds Voting Control
Beneficial Ownership Update
PAVmed Inc. filed an Amendment No. 6 to its Schedule 13D, detailing an updated beneficial ownership of 27.5% in Lucid Diagnostics Inc. and new agreements impacting voting control.
Summary
- PAVmed Inc. maintains a 27.5% beneficial ownership of Lucid Diagnostics Inc. common stock, totaling 38,816,903 shares.
- PAVmed, as the parent company, holds significant influence over the election of directors and other corporate matters at Lucid Diagnostics.
- A new Amendment Agreement dated February 3, 2026, grants a holder of PAVmed's 2026 Note the right to receive 300,000 shares of Lucid Diagnostics common stock by February 3, 2029, or earlier.
- PAVmed entered into a Voting Agreement on October 9, 2025, securing a proxy over 3,177,500 common stock votes and 4,063,286 other capital stock votes from a Lucid Diagnostics stockholder.
- Previous voting agreements with Lucid Diagnostics officers cover an additional 4,336,959 common stock votes.
- Existing agreements between PAVmed and Lucid Diagnostics, including a Security and Pledge Agreement, Management Services Agreement (MSA), and Payroll and Benefit Expense Reimbursement Agreement (PBERA), remain in effect.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a moderately positive update for PAVmed's control over Lucid, solidifying its influence through new voting agreements, though the future share transfer to a note holder introduces a minor potential for dilution for PAVmed shareholders.
Positives
- Increased voting control for PAVmed through new and existing voting agreements, solidifying its influence as the parent company over Lucid Diagnostics.
Negatives
- The right granted to a note holder to receive 300,000 shares of Lucid Diagnostics common stock from PAVmed could lead to future dilution for PAVmed shareholders if those shares are sourced from PAVmed's existing holdings or newly issued.
Risks
- Future acquisitions or sales of Lucid Diagnostics securities by PAVmed or its principals could impact market price, though no present intention to do so exists beyond described agreements.
- The beneficial ownership limitation described in the Amendment Agreement could affect the timing or execution of the share transfer to the 2026 Note holder.
Future Outlook
PAVmed Inc. intends to continuously review its ownership of Lucid Diagnostics Inc. and may acquire or sell additional securities based on an ongoing evaluation of Lucid's business, financial condition, market conditions, and alternative investment opportunities. No present intention to acquire or sell exists beyond the described agreements.
Industry Context
StockSavvy.ai notes that Schedule 13D/A filings are common for parent companies or significant shareholders to update their beneficial ownership and any related agreements. PAVmed's continued consolidation of voting control over Lucid Diagnostics, its subsidiary, is a typical move to ensure strategic alignment and operational control within a corporate structure. The granting of Lucid shares to a PAVmed note holder reflects inter-company financing arrangements.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Voting Control | PAVmed Inc. secured a new voting proxy over 3,177,500 common stock votes and 4,063,286 other capital stock votes from a Lucid Diagnostics stockholder, in addition to existing voting agreements with officers. | 2025-10-09 | Strengthens PAVmed's ability to influence director elections and other corporate matters at Lucid Diagnostics. |
| Share Transfer Obligation | PAVmed Inc. granted a holder of its 2026 Note the right to receive 300,000 shares of Lucid Diagnostics common stock. | 2026-02-03 | Establishes a future obligation for PAVmed to transfer Lucid shares, potentially impacting PAVmed's beneficial ownership percentage over time. |
Related Party Transactions
- Management Services Agreement (MSA) between PAVmed Inc. (parent company) and Lucid Diagnostics Inc. (subsidiary), amended from time to time.
- Payroll and Benefit Expense Reimbursement Agreement (PBERA) between PAVmed Inc. and Lucid Diagnostics Inc., amended from time to time.
- Certain principals of PAVmed Inc. have been granted restricted stock and/or stock option awards as compensation by Lucid Diagnostics Inc.
Stakeholder Impact
- Shareholders (PAVmed): Potential future dilution if PAVmed sources the 300,000 Lucid shares from its existing holdings or new issuance to fulfill the Amendment Agreement.
- Shareholders (Lucid Diagnostics): Increased certainty of PAVmed's continued strategic influence and control as the parent company due to strengthened voting agreements.
- Creditors (PAVmed): The 2026 Note holder has a right to receive Lucid shares, which is part of the terms of their financing arrangement with PAVmed.
Next Steps
- PAVmed Inc. will continue to review its ownership of Lucid Diagnostics Inc. on an ongoing basis.
- PAVmed may acquire additional securities or sell existing holdings of Lucid Diagnostics based on various factors, though no present intention exists beyond the described agreements.
- Transfer of 300,000 shares of Lucid Diagnostics common stock from PAVmed to the 2026 Note holder by February 3, 2029, or earlier.
Key Dates
| Date | Description |
|---|---|
| 2018-05-12 | Original date of the Management Services Agreement (MSA) between PAVmed and Lucid Diagnostics. |
| 2021-10-27 | Original filing date of the Schedule 13D by PAVmed Inc. regarding Lucid Diagnostics Inc. |
| 2022-04-04 | Date of the Security and Pledge Agreement between PAVmed Inc. and the Holder of the 2026 Note. |
| 2022-11-30 | Original date of the Payroll and Benefit Expense Reimbursement Agreement (PBERA) between PAVmed and Lucid Diagnostics. |
| 2022-12-02 | Date of Amendment No. 1 to the Schedule 13D. |
| 2024-02-02 | Date of Amendment No. 2 to the Schedule 13D. |
| 2024-02-20 | Date of Amendment No. 3 to the Schedule 13D. |
| 2024-11-12 | Date of the Securities Purchase Agreement (Issuer Note SPA) for Lucid Diagnostics' convertible notes, involving PAVmed's voting obligations. |
| 2024-12-12 | Date of Amendment No. 4 to the Schedule 13D. |
| 2025-03-24 | Filing date of Lucid Diagnostics' Annual Report on Form 10-K, describing the MSA and PBERA. |
| 2025-10-09 | Date of the Voting Agreement between PAVmed Inc. and a Lucid Diagnostics stockholder. |
| 2025-10-10 | Date of Amendment No. 5 to the Schedule 13D. |
| 2026-02-03 | Date of the Amendment Agreement between PAVmed Inc. and the holder of the 2026 Note, and the date of the 2026 Note itself. |
| 2026-02-09 | Filing date of this Amendment No. 6 to the Schedule 13D. |
| 2029-02-03 | Maturity date of the 2026 Note, by which 300,000 shares of Lucid Diagnostics common stock are to be transferred to the note holder. |
Recommendation
holdThe filing primarily details an update to beneficial ownership and voting agreements by PAVmed Inc. in its subsidiary, Lucid Diagnostics Inc. While PAVmed is solidifying its control, which can be seen as a positive for strategic alignment, there are no new financial results or significant operational updates to warrant a change in investment thesis. The future transfer of Lucid shares to a PAVmed note holder is a minor event in the context of overall ownership. Therefore, a 'hold' recommendation is appropriate as the filing does not present new information that fundamentally alters the company's valuation or outlook, but rather clarifies existing control structures.
Keywords
Lucid Diagnostics, PAVmed Inc., Schedule 13D/A, Beneficial Ownership, Voting Control, Common Stock, SEC Filing, Corporate Governance, Parent Company, Convertible Note, Voting Proxy
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.